4506.T Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 08:15):

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally...

Stats
Tagesvolumen	1.42M
Durchschnittsvolumen	3.35M
Marktkapitalisierung	162.89B
EPS	¥0 ( 2024-01-31 )
Nächstes Ertragsdatum	( ¥-323.99 ) 2024-05-13
Last Dividend	¥7.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	-0.940
ATR14	¥0.448 (0.11%)

Volumen Korrelation

Lang: 0.25 (neutral)

Kurz: 0.26 (neutral)

Signal:(64.01) Neutral

Sumitomo Pharma Co., Ltd. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Sumitomo Pharma Co., Ltd. Korrelation - Währung/Rohstoff

0.66
( moderate )

0.74
( moderate )

0.55
( weak )

0.75
( moderate )

-0.02
( neutral )

-0.61
( weak negative )

Sumitomo Pharma Co., Ltd. Finanzdaten

Annual	2022
Umsatz:	¥555.54B
Bruttogewinn:	¥376.63B (67.79 %)
EPS:	¥-187.55

FY	2022
Umsatz:	¥555.54B
Bruttogewinn:	¥376.63B (67.79 %)
EPS:	¥-187.55

FY	2022
Umsatz:	¥560.04B
Bruttogewinn:	¥402.91B (71.94 %)
EPS:	¥102.19

FY	2021
Umsatz:	¥515.95B
Bruttogewinn:	¥378.18B (73.30 %)
EPS:	¥141.50

Financial Reports:

No articles found.

Sumitomo Pharma Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥14.00 (N/A)	¥0 (N/A)	¥7.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Sumitomo Pharma Co., Ltd. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥4.75	2000-03-28
Last Dividend	¥7.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	47	--
Total Paid Out	¥382.25	--
Avg. Dividend % Per Year	0.00%	--
Score	1.47	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-07-03)

¥6.79 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

1.47

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9368.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7989.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
7226.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6464.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
5563.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
4486.T	Ex Dividend Knight	2023-12-28	Annually	0.00%
3661.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
2915.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
1768.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9948.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.526	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.164	1.200	-5.46	-6.56	[0 - 0.3]
returnOnEquityTTM	-0.440	1.500	-6.00	-9.00	[0.1 - 1]
payoutRatioTTM	-0.0161	-1.000	-0.161	0.161	[0 - 1]
currentRatioTTM	0.627	0.800	-1.864	-1.491	[1 - 3]
quickRatioTTM	0.333	0.800	-2.75	-2.20	[0.8 - 2.5]
cashRatioTTM	0.0866	1.500	-0.630	-0.945	[0.2 - 2]
debtRatioTTM	0.389	-1.500	3.52	-5.29	[0 - 0.6]
interestCoverageTTM	-8.87	1.000	-4.40	-4.40	[3 - 30]
operatingCashFlowPerShareTTM	-693.01	2.00	-10.00	-10.00	[0 - 30]
freeCashFlowPerShareTTM	-728.72	2.00	-10.00	-10.00	[0 - 20]
debtEquityRatioTTM	1.199	-1.500	5.20	-7.81	[0 - 2.5]
grossProfitMarginTTM	0.599	1.000	3.34	3.34	[0.2 - 0.8]
operatingProfitMarginTTM	-0.536	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.669	1.000	-4.83	-4.83	[0.2 - 2]
assetTurnoverTTM	0.312	0.800	-1.256	-1.005	[0.5 - 2]
Total Score				-5.81

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.938	1.000	-0.196	0	[1 - 100]
returnOnEquityTTM	-0.440	2.50	-3.86	-9.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-728.72	2.00	-10.00	-10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-693.01	2.00	-10.00	-10.00	[0 - 30]
payoutRatioTTM	-0.0161	1.500	-0.161	0.161	[0 - 1]
pegRatioTTM	-2.71	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.834	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-5.01

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.